JNJ-27548547

DB15372InvestigationalSmall molecule

JNJ-27548547 is under investigation in clinical trial NCT01705002 (Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors.).

Formula / weight: C₆₂H₉₈N₄O₁₁S₂ · 1139.6 g/mol (avg)
Also known as: PROMITIL
Code names: JNJ-27548547

Resolves to

Compound

UNII3I8JKL1CHBCAS303983-00-8

Structure

InChIKeyLIHIIWJRSSLKKX-YCTALCSSSA-NSMILES

CCCCCCCCCCCCCCCCCC(=O)OCC(CSSC1=CC=C(COC(=O)N2[C@H]3CN4C5=C([C@@H](COC(N)=O)[C@@]4(OC)[C@@H]23)C(=O)C(N)=C(C)C5=O)C=C1)OC(=O)CCCCCCCCCCCCCCCCC

What you can answer from here — as of April 02, 2025

4Clinical trialsPhase, status and sponsor resolved per trial

Which companies are running trials of JNJ-27548547, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account